Lv21
160 积分 2026-09-18 加入
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
11天前
已完结
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
13天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
18天前
已完结
Therapy with oncolytic viruses: progress and challenges
24天前
已完结
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
25天前
已完结
Immunotherapy for hepatocellular carcinoma
1个月前
已完结
Targeting the hippo pathway in cancer
1个月前
已完结
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer
1个月前
已完结
Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma
1个月前
已完结
皖公网安备34019202002308
